Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APG-265
- Development stage
- Preclinical
- Lead developer
- Ascentage Pharma
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
APG-265 is a preclinical proteolysis-targeting chimera (PROTAC) MDM2 degrader being developed by Ascentage Pharma to reactivate the p53 tumor suppressor pathway in cancer. By inducing ubiquitination and proteasomal degradation of the E3 ligase MDM2, APG-265 is designed to relieve negative regulation of wild-type p53, thereby promoting p53-dependent cell-cycle arrest and apoptosis in tumor cells with intact TP53. APG-265 is part of Ascentage Pharma’s apoptosis-focused oncology pipeline and represents a targeted, mechanism-based antineoplastic agent for hematologic malignancies and solid tumors characterized by functional p53 and MDM2 dependence.[3][6][7][9]
02
Targets
MDM2 (Mouse double minute 2 homolog)
Beyond the preview
Go deeper on APG-265.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APG-265.